RECRUITING

Cognitive Assessment Tools for Huntington's Disease.

Description

The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.

Conditions

Huntington Disease
Talk to us

Related Conditions:

Huntington Disease

Study Overview

On this page

Study Details

Study overview

The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.

Cognitive Assessment Tools for Individuals With Huntington's Disease.

Cognitive Assessment Tools for Huntington's Disease.

Condition
Huntington Disease
Intervention / Treatment

-

Contacts and Locations

Columbus

The Ohio State University Wexner Medical Center, Columbus, Ohio, United States, 43221

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.
  • 2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.
  • 3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.
  • 4. Vision and hearing sufficient for compliance with tests.
  • 5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form.
  • 1. Age of symptom onset less than 19 years old or greater than 60 years old.
  • 2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant.
  • 3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure).
  • 4. Subjects who are pregnant or breast feeding
  • 5. Subjects with a history of a learning disability.
  • 6. Subjects who are unable to provide consent.

Ages Eligible for Study

30 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ohio State University,

Study Record Dates

2025-12-01